Autism Spectrum DisorderNCT05192109

Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)

A study testing Overheard Speech and Addressed Speech in people with Autism Spectrum Disorder, run by New York University at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children). Specific Aim 2 (Experiment 2): Determine whether children with ASD can learn from addressed and overheard teaching via videoconferencing. Read more about this study

Who is it for?: Ages 18 to 71 monthsHealthy volunteers can take part
Conditions the study is for: Autism Spectrum Disorder
What is being tested?: Overheard Speech and Addressed Speech
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 342 participants
Where: 2 sitesUnited States
Study dates: 1 Dec 2020to 5 Dec 2024
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 71 months
All sexes
Healthy volunteers accepted
Child

Who may be able to join

children with or without a diagnosis of ASD between 18 to 71 months of age

Who cannot join

native language is not English born premature (< 36 weeks) has uncorrected hearing or vision impairments has developmental disorders or medical conditions other than ASD that affect language or cognition (excepting psychiatric conditions often comorbid with ASD such as ADHD) has a history of photosensitive epileptic seizures

Trial locations and contacts

2 sites in 1 country.

United States2 sites

Emerson College
Boston, Massachusetts, 02116
New York University
New York, New York, 10012

Other trials in United States

About this study

The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children).

Specific Aim 2 (Experiment 2): Determine whether children with ASD can learn from addressed and overheard teaching via videoconferencing. The investigators will use a similar procedure to Study 1, except that both overheard and directed teaching will take place on video.

Conditions: Autism Spectrum Disorder
Being tested: Overheard Speech, Addressed Speech
Medical subject headings: Autism Spectrum Disorder

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Overheard SpeechBehavioural
New words are introduced with the child as a bystander rather directly taught.
Addressed SpeechBehavioural
New words are introduced directly to the child by an experimenter.

Study groups in NCT05192109
Study group	Role	What they receive
Addressed	Experimental	Children participate via video in an interaction with an experimenter who uses the word to be learned. Receives: Behavioral: Addressed Speech
Overheard	Experimental	Children watch via video while an experimenter uses the word to be learned in an interaction with another experimenter. Receives: Behavioral: Overheard Speech

What is being measured

The primary outcome is the main question the study is designed to answer.

Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object
Children's eye gaze is recorded as they look at images. The proportion of time during which gaze is directed to an image of the targeted word is the dependent measure.
Measured: immediately after viewing 3-minute interaction
Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object
Children's eye gaze is recorded as they look at images. The proportion of time during which gaze is directed to an image of the targeted word is the dependent measure.
Measured: 5 minutes after viewing interaction

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Dec 20205 Dec 2024

First posted14 Jan 2022
Study start1 Dec 2020
Primary completion1 Dec 2024
Study completion5 Dec 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Basic science
Allocation: Non-randomised
Intervention model: Crossover
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 342 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05192109
Sponsor's protocol ID: 280522
Status last verified: Nov 2024
First submitted: 3 Jan 2022
Last updated: 1 Apr 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
Transdiagnostic Sleep and Circadian Treatment for Autistic Adolescents
Sleep, Autism Spectrum Disorder
RecruitingPhase 2
TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS
Autism Disorder
RecruitingObservational study
Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare
Autism Spectrum Disorder
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Recruiting
Word Learning From Parentese in Autistic Children
Autism, Autism Spectrum Disorder

All Autism Spectrum Disorder trials

Study at a glance

From the registry record, last updated by the sponsor on 1 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Study 2: Learning New Words From Overhearing in Children With Autism Spectrum Disorder (ASD)
ClinicalTrials.gov ID: NCT05192109
Acronym / sponsor ID: 280522
Conditions: Autism Spectrum Disorder
Study type: Interventional
Recruitment status: Completed
Enrolment: 342 participants (actual)
Lead sponsor: New York UniversityUniversity, hospital or other
Collaborators: Emerson College
Study start: 1 Dec 2020 (actual)
Primary completion: 1 Dec 2024 (actual)
Study completion: 5 Dec 2024 (actual)
First posted: 14 Jan 2022 (actual)
Results: Posted 20 Mar 2025

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The goal of this research is to explore abilities to learn word meanings from overheard conversations in children with ASD (and, as a control, typically developing children).

Study design

Primary purpose: Basic science
Allocation: Non-randomised
Intervention model: Crossover
Masking: Single blind (outcomes assessor)
Number of arms: 2

Arm	Type	Receives
Addressed	Experimental	Behavioral: Addressed SpeechChildren participate via video in an interaction with an experimenter who uses the word to be learned.
Overheard	Experimental	Behavioral: Overheard SpeechChildren watch via video while an experimenter uses the word to be learned in an interaction with another experimenter.

Who may qualify

Ages: 18 to 71 months
Sex: All
Healthy volunteers: Accepted
Age groups: Child

Key inclusion criteria (1 listed)

children with or without a diagnosis of ASD between 18 to 71 months of age

Key exclusion criteria (1 listed)

native language is not English born premature (< 36 weeks) has uncorrected hearing or vision impairments has developmental disorders or medical conditions other than ASD that affect language or cognition (excepting psychiatric conditions often comorbid with ASD such as ADHD) has a history of photosensitive epileptic seizures

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Overheard SpeechNew words are introduced with the child as a bystander rather directly taught.	Behavioural	Overheard
Addressed SpeechNew words are introduced directly to the child by an experimenter.	Behavioural	Addressed

Primary outcome

Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object
Time frame: immediately after viewing 3-minute interaction
Children's eye gaze is recorded as they look at images. The proportion of time during which gaze is directed to an image of the targeted word is the dependent measure.
Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object
Time frame: 5 minutes after viewing interaction
Children's eye gaze is recorded as they look at images. The proportion of time during which gaze is directed to an image of the targeted word is the dependent measure.

Results and safety

Results posted to the registry on 20 Mar 2025, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
ASD - Addressed First, Then Overheard	87	78
ASD - Overheard First, Then Addressed	89	78
TD - Addressed First, Then Overheard	85	83
TD - Overheard First, Then Addressed	81	79

Primary outcome: Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object

Time frame: immediately after viewing 3-minute interaction. Mean (Standard Deviation). Unit: proportion of time

Measure	ASD - Addressed n = 80	ASD - Overheard n = 82	TD - Addressed n = 106	TD - Overheard n = 104
Value	0.42 (0.35)	0.44 (0.33)	0.49 (0.34)	0.38 (0.31)

ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p <0.01, Regression, Linear
ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p = 0.93, Regression, Linear
ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p <0.01, Regression, Linear

Population analysed: Not all enrolled participants were analyzed because of exclusions due to, e.g., experimenter error or children paying insufficient attention.

Primary outcome: Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object

Time frame: 5 minutes after viewing interaction. Mean (Standard Deviation). Unit: proportion of time

Measure	ASD - Addressed n = 73	ASD - Overheard n = 77	TD - Addressed n = 98	TD - Overheard n = 92
Value	0.43 (0.34)	0.30 (0.32)	0.42 (0.34)	0.43 (0.32)

ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p <0.01, Regression, Linear
ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p = 0.22, Regression, Linear
ASD - Addressed vs ASD - Overheard vs TD - Addressed vs TD - Overheard: p <0.01, Regression, Linear

Population analysed: Not all enrolled participants were analyzed because of exclusions due to, e.g., experimenter error or children paying insufficient attention.

Adverse events

Time frame: the duration of study participation (approximately 10 minutes). Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
ASD - Addressed	0 of 176 (0%)	0 of 176 (0%)	0 of 176
ASD - Overheard	0 of 176 (0%)	0 of 176 (0%)	0 of 176
TD - Addressed	0 of 166 (0%)	0 of 166 (0%)	0 of 166
TD - Overheard	0 of 166 (0%)	0 of 166 (0%)	0 of 166

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Individual participant dataSharing planned: No

Related trials for Autism Spectrum Disorder

Not yet recruiting
Transdiagnostic Sleep and Circadian Treatment for Autistic Adolescents
Sleep, Autism Spectrum Disorder
RecruitingPhase 2
TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS
Autism Disorder
RecruitingObservational study
Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare
Autism Spectrum Disorder
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Recruiting
Word Learning From Parentese in Autistic Children
Autism, Autism Spectrum Disorder

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

2 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing Overheard Speech and Addressed Speech in people with Autism Spectrum Disorder, run by New York University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Mar 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of Time During Which Children's Eye Gaze is Directed Toward the Target Object (time frame: immediately after viewing 3-minute interaction). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05192109.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026.